SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine
The Supreme Court of Korea has sided with SK in an ongoing patent feud with Pfizer, ruling that the Korean company did not violate a composition patent on Pfizer’s pneumococcal shot Prevnar 13 by shipping components and finished research doses of its own 13-valent immunization, PCV13, to Russia.
The Supreme Court of Korea has sided with SK in an ongoing patent feud with Pfizer, ruling that the Korean company did not violate a composition patent on Pfizer’s pneumococcal shot Prevnar 13 by shipping components and finished research doses of its own 13-valent immunization, PCV13, to Russia.
